A Comparison Of Nebulisation With Dexmedetomidine And Nebulisation With 4% Lignocaine Plus Dexmedetomidine For Awake Fibreoptic Intubation

A Comparative Evaluation Of Efficacy Of Nebulisation With Dexmedetomidine And Nebulisation With 4% Lignocaine Plus Dexmedetomidine For Awake Fibreoptic Intubation In Difficult Airway Scenario: A Randomized Control Trial

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/10/037256

Enrollment

Registered

2021-10-11

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: - Health Condition 2: O- Medical and Surgical

Interventions

Intervention1: Dexmedetomidine hydrochloride with lignocaine hydrochloride: The study will be conducted on 80 patients with difficult airway (LEMON 2),randomly allocated in 2 groups of 40 each. Group

Eligibility

Inclusion criteria

Inclusion criteria: patient consent, ASA grade 1 and 2, patient with anticipated difficult intubation(LEMON >2), BMI >30 kg/m2

Exclusion criteria

Exclusion criteria: patient refusal, airway hypersensitivity, allergy to drugs used (lignocaine/dexmedetomidine),epileptic patients,patients with poor cardiopulmonary reserve, bleeding tendency, obesity, other co-morbid conditions

Design outcomes

Primary

Measure	Time frame
1.sedation/alertness(OAA SCORE) 2.vocal cord movement(%) 3.limb movement 4.fibreoptic intubation score 5.coughingTimepoint: 0 to 5 min	—

Secondary

Measure	Time frame
1) To compare the hemodynamic changes of two groups 2) Dose sparing effect of propofolTimepoint: 0 min,1 min, 2 min , 3 min, 4 min, 5 min	—

Countries

India

Contacts

Public ContactDr Arvind Kumar

IGIMS,PATNA

arvind007kumar@yahoo.com8789655581

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026